From Our 2007 Archives
U.S. Heart Failure Program Is Saving Lives
Latest MedicineNet News
MONDAY, July 23 (HealthDay News) -- A national program to improve heart-failure patient care in U.S. hospitals is working, researchers say.
Heart failure occurs when the heart can't pump enough blood to the body's other organs. The disease affects five million Americans, and nearly 3.6 million people are hospitalized with heart failure each year.
A new study in the July 23 issue of the Archives of Internal Medicine evaluated an initiative called the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).
Adopted by the American Heart Association's Get With the Guidelines-Heart Failure quality improvement program and sponsored by drug maker GlaxoSmithKline, OPTIMIZE-HF is the largest effort of its kind undertaken for U.S. heart failure patients, with 259 hospitals participating. It is designed to help hospitals increase their adherence to standard hospital-based performance measures.
OPTIMIZE-HF also provides hospitals with tools to help improve the reliability of care, including standardized admission orders, discharge checklists, pocket cards, medical chart stickers, best-practice algorithms and critical pathways.
For the study, researchers looked at data from OPTIMIZE-HF's heart-failure performance-improvement registry, a Web-based program that allows hospitals to review and compare their data to data from similar facilities. Information in the registry included data on admission, discharge care and outcomes (e.g., death and re-hospitalization rates).
Between March 2003 and December 2004, 48,612 heart failure patients were enrolled in the registry. A subgroup of 5,791 patients were followed for an additional 60-90 days after they were discharged from the hospital.
The researchers found improvements in three of four of the Joint Commission on Accreditation of Healthcare Organization's performance measures used to gauge the quality of heart failure care in hospitals. They included:
A fourth measure, involving prescribing an angiotensin-converting enzyme or angiotensin II receptor blocker medication at discharge, remained steady during the study.
The researchers found other improvements, as well. The use of beta-blockers rose from 78 percent to 86 percent, prescribing aldosterone antagonists increased from 11 percent to 20 percent, and the use of statin medications rose from 39 percent to 44 percent.
The rate of patient death while at the hospital dropped from 4.1 percent to 2.5 percent when hospitals used the standardized admission orders, and rates of death or hospitalization after hospital discharge decreased from 38.2 percent to 34.8 percent when the tools were used during care, the researchers found.
Another favorable outcome -- a decrease in deaths after hospital discharge from 9.9 percent to 6.3 percent -- could save thousands of lives if all hospitals participated in the initiative. In addition, the length of hospital stays dropped from 7.5 days to 6.2 days.
"If similar improvements had occurred at hospitals nationwide, this would translate to 40,000 less deaths and 1.4 million costly hospital days eliminated per year," principal investigator Dr. Gregg C. Fonarow, UCLA's Eliot Corday chair in cardiovascular medicine and science, director of the Ahmanson-UCLA Cardiomyopathy Center and professor of medicine at the David Geffen School of Medicine at UCLA, said in a prepared statement.
"Despite compelling scientific evidence and national guidelines for use of key life-prolonging agents and lifestyle changes, gaps exist in heart failure treatment," Fonarow said. "We hope more hospitals will adopt this validated model for enhancing heart-failure patient care."
-- Krisha McCoy
SOURCE: University of California, Los Angeles, Health Sciences, news release, July 23, 2007
Copyright © 2007 ScoutNews, LLC. All rights reserved.
- Allergic Skin Disorders
- Bacterial Skin Diseases
- Bites and Infestations
- Diseases of Pigment
- Fungal Skin Diseases
- Medical Anatomy and Illustrations
- Noncancerous, Precancerous & Cancerous Tumors
- Oral Health Conditions
- Papules, Scales, Plaques and Eruptions
- Scalp, Hair and Nails
- Sexually Transmitted Diseases (STDs)
- Vascular, Lymphatic and Systemic Conditions
- Viral Skin Diseases
- Additional Skin Conditions